Nutriband Inc. (NASDAQ:NTRB) Sees Significant Decline in Short Interest

Nutriband Inc. (NASDAQ:NTRBGet Free Report) was the recipient of a large decrease in short interest in the month of June. As of June 15th, there was short interest totalling 56,300 shares, a decrease of 14.3% from the May 31st total of 65,700 shares. Based on an average trading volume of 62,000 shares, the days-to-cover ratio is presently 0.9 days. Approximately 1.0% of the shares of the stock are sold short.

Nutriband Price Performance

NASDAQ:NTRB opened at $5.40 on Friday. The stock has a fifty day moving average price of $4.69 and a 200-day moving average price of $3.56. The company has a current ratio of 6.16, a quick ratio of 6.04 and a debt-to-equity ratio of 0.03. Nutriband has a fifty-two week low of $1.53 and a fifty-two week high of $6.75.

Nutriband (NASDAQ:NTRBGet Free Report) last released its earnings results on Friday, May 31st. The company reported ($0.21) earnings per share for the quarter. The company had revenue of $0.41 million for the quarter. Nutriband had a negative net margin of 315.56% and a negative return on equity of 71.77%.

Institutional Trading of Nutriband

An institutional investor recently bought a new position in Nutriband stock. Virtu Financial LLC purchased a new position in shares of Nutriband Inc. (NASDAQ:NTRBFree Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 12,862 shares of the company’s stock, valued at approximately $58,000. Virtu Financial LLC owned approximately 0.12% of Nutriband as of its most recent filing with the SEC. 19.70% of the stock is currently owned by hedge funds and other institutional investors.

About Nutriband

(Get Free Report)

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.

Further Reading

Receive News & Ratings for Nutriband Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutriband and related companies with MarketBeat.com's FREE daily email newsletter.